ACL Digital strengthens position with Symbiance acquisition

Core Insights - ACL Digital has acquired US-based contract research organization (CRO) Symbiance to enhance its global position as a provider of end-to-end clinical research and data solutions [1] - The acquisition strengthens ACL Digital's life sciences portfolio by adding specialized expertise in various areas including pharmacovigilance, medical writing, biostatistics, data standardization, clinical data management, and statistical programming [1] Company Strategy - The acquisition aligns with ACL Digital's growth strategy, enhancing capabilities to deliver patient-centric and transformative solutions that exceed life sciences industry standards [2] - The combined strengths of ACL Digital's AI-powered offerings and Symbiance's clinical research expertise will enable the company to meet the industry's AI transformation needs [3] Operational Efficiency - The acquisition is expected to accelerate innovation and drive operational efficiency for clients in the biotech, pharmaceutical, and medical device sectors globally [3] - Symbiance's established reputation in the US for quality and delivery reflects the expertise of its leadership and team, which will benefit ACL Digital [4] Future Readiness - The acquisition underscores ACL Digital's commitment to becoming a global leader in digital solutions for clinical research, strengthening its position in the life sciences and CRO space [5] - The 'people + product' delivery model of Symbiance, supported by tools and AI-driven analytics, will enhance ACL Digital's capabilities and service offerings for current and future clients [5]